Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Date:3/17/2008

PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical and preclinical abstracts are expected to be the subject of oral or poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Dendritic and T cell functions in patients with metastatic hormone-

refractory prostate cancer treated with GVAX immunotherapy for prostate

cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session)

- Oral presentation scheduled for Monday, April 14, 2008 at 1:25 p.m.

-- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent

induction of CD8+ T cell activation and clinical responses" (Abstract

#2539, Clinical Immunotherapy Session) - Oral presentation scheduled

for Monday, April 14, 2008 at 1:40 p.m.

-- "Increased doses of an anti-CD30 antibody, MDX-060, results in

prolonged progression free survival in subjects with CD30 positive

lymphoma" (Abstract #5525, Phase 2 and 3 Clinical Trials 3: Blood,

Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for

Wednesday, April 16, 2008 at 8:00 a.m.

-- "Preclinical development of anti B7-H4 therapeutic antibodies"

(Abstract #4986, Developmental Immunotherapy Session) - Oral

presentation scheduled for Tuesday, April 15, 2008 at 2:25 p.m.

-- "Human antibody conjugates of potential utility for prostate cancer

therapy: a comparison of MGBA conjugates with antibodies targeting a

cell surface target (prostate-specific membrane antigen) and an extra-

cellular target (Mindin/RG1)" (Abstract #4062, Immunoconjugates,

Peptides, and Protein Therapeutics Session) - Poster session scheduled

for Tuesday, April 15, 2008 at 8:00 a.m.

-- "Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate"

(Abstract #4061, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 at 8:00

a.m.

-- "Mechanism of activation of a human anti-CD70 antibody-MGBA conjugate

and efficacy in a nude rat model of renal carcinoma" (Abstract #4057,

Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster

session scheduled for Tuesday, April 15, 2008 at 8:00 a.m.

-- "Ptk7 as a direct and tumor stroma target in multiple solid

malignancies" (Abstract #1526, Targets and Screening Approaches

Session) - Poster session scheduled for Sunday, April 13, 2008 at 1:00

p.m.

Abstracts and information about the AACR and its Annual Meeting may be found at http://www.aacr.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
2. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
3. Medarex Announces Completion of Sale of Shares in Genmab A/S
4. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
5. Medarex Announces Election of Marc Rubin as New Board Member
6. Medarex to Present at the UBS Global Life Sciences Conference
7. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
8. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
9. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
10. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):